Suven Life Sciences : Schedule of Conference Call for Investors on May 26, 2023
May 19, 2023 at 07:42 am EDT
Share
CSD/BSE&NSE/CC/2023-24
May 19, 2023
To
To
The Manager
The Manager
Department of Corporate Services
Listing Department
BSE Limited
National Stock Exchange of India Limited
25th Floor, P. J. Towers,
Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400 001
Bandra (E), Mumbai - 400 051
Scrip Code: 543064
Scrip Symbol: SUVENPHAR
Dear Sir/Madam,
Sub: Schedule of Conference Call for Investors
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Friday, May 26, 2023 at 12:00 Noon IST to
discuss the Audited Financial Results for the Q4 & FY23, to be declared on May 25, 2023.
This is for your information and record.
Thanking You,
Yours faithfully,
For Suven Pharmaceuticals Limited
HANUMANT HA RAO KOKKONDA
Digitally signed by
HANUMANTHA RAO KOKKONDA
Date: 2023.05.19 15:52:50 +05'30'
K Hanumantha Rao
Company Secretary
Encl: as above
Suven Pharmaceuticals Limited
Registered Office: # 8-2-334 I SDE Serene Chambers I 3rd Floor I Road No.5
Avenue 7 I Banjara Hills I Hyderabad - 500034 I Telangana I India I CIN: L24299TG2018PLC128171
Tel: 91 40 2354 9414 /1142 /3311 I Fax: 91 40 2354 1152 I Email: info@suvenpharm.com I www.suvenpharm.com
Suven Pharmaceuticals Ltd to host Q4 & FY23 Results
Conference call on Friday, May 26, 2023 @ 12 noon
Suven Pharmaceuticals Ltd will be conducting a conference call to discuss its Q4 & FY23 results performance. Suven Pharmaceuticals Ltd will be represented by members of the senior management team.
The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As. The financial results will be announced earlier on May 25, 2023.
In order to pre-register: Copy this URL in your browser:
Suven Life Sciences Limited published this content on 19 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 May 2023 11:41:06 UTC.
Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.